Publications
- Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics2016 | Publication without faculty affiliation
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease2016 | Publication without faculty affiliation
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease2016 | Publication without faculty affiliation
- Rhythm versus rate control in patients with newly diagnosed atrial fibrillation - Observations from the GARFIELD-AF registry2023 | Publication without faculty affiliation
- Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial2022 | Publication without faculty affiliation
- Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial2022 | Publication without faculty affiliation
- Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial2022 | Publication without faculty affiliation
- On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease2022 | Publication without faculty affiliation
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin2021 | Publication without faculty affiliation
- Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants2021 | Publication without faculty affiliation
Loading network view...